DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xie, M.
Right arrow Articles by Yan, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xie, M.
Right arrow Articles by Yan, B.

Vol. 31, Issue 1, 21-27, January 2003

Mouse Liver and Kidney Carboxylesterase (M-LK) Rapidly Hydrolyzes Antitumor Prodrug Irinotecan and the N-Terminal Three Quarter Sequence Determines Substrate Selectivity

Mingxing Xie, Dongfang Yang, Micheal Wu, Bob Xue, and Bingfang Yan

Department of Biomedical Sciences, University of Rhode Island, Kingston, Rhode Island (M.X., D.Y., B.X., B.Y.); and Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois (M.W.)

Antitumor prodrug irinotecan is used for a variety of malignancies such as colorectal cancer. It is hydrolyzed to the metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), which exerts its antineoplastic effect. Several human and rodent carboxylesterases are shown to hydrolyze irinotecan, but the overall activity varies from enzyme to enzyme. This report describes a novel mouse liver and kidney carboxylesterase (M-LK) that is highly active toward this prodrug. Northern analyses demonstrated that M-LK was abundantly expressed in the liver and kidney and slightly in the intestine and lung. Lysates from M-LK transfected cells exhibited a markedly higher activity on irinotecan hydrolysis than lysates from the cells transfected with mouse triacylglycerol hydrolase (TGH) (6.9 versus 1.3 pmol/mg/min). Based on the immunostaining intensity with purified rat hydrolase A, M-LK had a specific activity of 173 pmol/mg/min, which ranked it as one of the most efficient esterases known to hydrolyze irinotecan. A chimeric carboxylesterase and its wild-type enzyme (e.g., M-LKn and M-LK), sharing three quarters of the entire sequence from the N-terminus, exhibited the same substrate preference toward irinotecan and two other substrates, suggesting that the N-terminal sequence determines substrate selectivity. M-LK transfected cells manifested more severe cytotoxicity than TGH transfected cells upon being exposed to irinotecan. Topoisomerase I inhibitors such as irinotecan represent a promising class of anticancer drugs. Identification of M-LK as an efficient carboxylesterase to activate irinotecan provides additional sequence information to locate residues involved in irinotecan hydrolysis and thus facilitates the design of new analogs.


Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
Y. Ma, K. Sachdeva, J. Liu, M. Ford, D. Yang, I. A. Khan, C. O. Chichester, and B. Yan
DESMETHOXYYANGONIN AND DIHYDROMETHYSTICIN ARE TWO MAJOR PHARMACOLOGICAL KAVALACTONES WITH MARKED ACTIVITY ON THE INDUCTION OF CYP3A23
Drug Metab. Dispos., November 1, 2004; 32(11): 1317 - 1324.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Furihata, M. Hosokawa, N. Koyano, T. Nakamura, T. Satoh, and K. Chiba
IDENTIFICATION OF DI-(2-ETHYLHEXYL) PHTHALATE-INDUCED CARBOXYLESTERASE 1 IN C57BL/6 MOUSE LIVER MICROSOMES: PURIFICATION, CDNA CLONING, AND BACULOVIRUS-MEDIATED EXPRESSION
Drug Metab. Dispos., October 1, 2004; 32(10): 1170 - 1177.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. J. P. Yoon, J. L. Hyatt, C. L. Morton, R. E. Lee, P. M. Potter, and M. K. Danks
Characterization of inhibitors of specific carboxylesterases: Development of carboxylesterase inhibitors for translational application
Mol. Cancer Ther., August 1, 2004; 3(8): 903 - 909.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.